Member of the Board since 2022.
Britt Meelby Jensen was born in 1973 and is a Danish national. She received a MSc in International Marketing and Management from Copenhagen Business School in Denmark and furthermore received an MBA from Solvay Business School (Université Libre de Bruxelles) in Brussels.
Between 2000-2002, Britt Meelby Jensen worked as a Management Consultant in McKinsey & Company. She joined Novo Nordisk A/S in 2002 where she held several leadership roles, including being Corporate Vice President of Global Marketing, Market Access & Commercial Excellence. In 2013, Britt Meelby Jensen was appointed CEO of Dako A/S, a global cancer diagnostics company owned by Agilent Inc. From 2015-2019, she was President and CEO of the Danish public biotech company, Zealand Pharma A/S, where the company was listed on Nasdaq in the US. From 2019-2022, Britt Meelby Jensen served as CEO of Swedish Medtech company, Atos Medical AB, owned by PAI partners, however, in connection with selling the company to Coloplast, Britt decided to step down from her role and continued as an advisor. In May 2022, Britt Meelby Jensen was appointed as CEO of Ambu A/S where had served as Board member since 2019.
Other Board Positions and Management Duties:
- CEO, Ambu A/S, Denmark
- Advisor, Novo Holdings A/S Advisory Group (NAG), Denmark.
- Board Member, Hempel Foundation and Hempel Invest A/S, Denmark